SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 27, 2009-- Exelixis, Inc. (Nasdaq:EXEL) will release its first quarter 2009 financial results on Thursday, May 7, 2009 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT, in which Exelixis management will discuss the financial results and provide a general business update. The webcast may be accessed on the Event Calendar page under Investors at www.exelixis.com.

An audio replay of the webcast will be available until 11:59 p.m. EDT/ 8:59 p.m. PDT on June 7, 2009. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 45146921.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company’s web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Executive Director,
Corporate Communications
cbutler@exelixis.com
Media Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager,
Corporate Communications
sharrison@exelixis.com